School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo

Simple item page
dc.contributor.authorDoyle, L.W.
dc.contributor.authorAnderson, P.J.
dc.contributor.authorHaslam, R.
dc.contributor.authorLee, K.J.
dc.contributor.authorCrowther, C.
dc.contributor.authorDarlow, B.
dc.contributor.authorAustin, N.
dc.contributor.authorFrench, N.
dc.contributor.authorCampbell, C.
dc.contributor.authorCarse, E.
dc.contributor.authorHayes, M.
dc.contributor.authorHarding, J.
dc.contributor.authorMcKinlay, C.
dc.contributor.authorBevan, C.
dc.contributor.authorDe Paoli, A.
dc.contributor.authorSutton, L.
dc.contributor.authorRieger, I.
dc.contributor.authorWocadlo, C.
dc.contributor.authorColditz, P.
dc.contributor.authorPritchard, M.
dc.contributor.authoret al.
dc.date.issued2014
dc.description.abstractIMPORTANCE: Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into school age have not been reported from randomized trials. OBJECTIVE: To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral outcomes at school age. DESIGN, SETTING, AND PARTICIPANTS: The ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation. Children who survived from the 14 centers who participated in the school-age follow-up (n = 443 magnesium; n = 424 placebo) were invited for an assessment at 6 to 11 years of age between 2005 and 2011. MAIN OUTCOMES AND MEASURES: Mortality, cerebral palsy, motor function, IQ, basic academic skills, attention and executive function, behavior, growth, and functional outcomes. Main analyses were imputed for missing data. RESULTS: Of the 1255 fetuses known to be alive at randomization, the mortality rate to school age was 14% (88/629) in the magnesium sulfate group and 18% (110/626) in the placebo group (risk ratio [RR], 0.80; 95% CI, 0.62-1.03, P = .08). Of 867 survivors available for follow-up, outcomes at school age (corrected age 6-11 years) were determined for 669 (77%). Comparing the magnesium sulfate and placebo groups revealed no statistically significant difference in proportions with cerebral palsy (23/295 [8%] and 21/314 [7%], respectively; odds ratio [OR], 1.26; 95% CI, 0.84-1.91; P = .27) or abnormal motor function (80/297 [27%] and 80/300 [27%], respectively; OR, 1.16; 95% CI, 0.88-1.52; P = .28). There was also little difference between groups on any of the cognitive, behavioral, growth, or functional outcomes. CONCLUSIONS AND RELEVANCE: Magnesium sulfate given to pregnant women at imminent risk of birth before 30 weeks' gestation was not associated with neurological, cognitive, behavioral, growth, or functional outcomes in their children at school age, although a mortality advantage cannot be excluded. The lack of long-term benefit requires confirmation in additional studies. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12606000252516.
dc.description.statementofresponsibilityLexW. Doyle, Peter J. Anderson, Ross Haslam, Katherine J. Lee, Caroline Crowther, for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group
dc.identifier.citationJournal of the American Medical Association (JAMA), 2014; 312(11):1105-1113
dc.identifier.doi10.1001/jama.2014.11189
dc.identifier.issn0098-7484
dc.identifier.issn1538-3598
dc.identifier.orcidCrowther, C. [0000-0002-9079-4451]
dc.identifier.orcidAshwood, P. [0000-0003-4654-3281]
dc.identifier.urihttp://hdl.handle.net/2440/96292
dc.language.isoen
dc.publisherJAMA
dc.rightsCopyright 2014 American Medical Association. All rights reserved.
dc.source.urihttps://doi.org/10.1001/jama.2014.11189
dc.subjectAustralasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group
dc.subjectHumans
dc.subjectCerebral Palsy
dc.subjectPremature Birth
dc.subjectMagnesium Sulfate
dc.subjectNeuroprotective Agents
dc.subjectTreatment Outcome
dc.subjectPrenatal Care
dc.subjectInfant Mortality
dc.subjectFollow-Up Studies
dc.subjectChild Development
dc.subjectCognition Disorders
dc.subjectMotor Skills Disorders
dc.subjectPregnancy
dc.subjectInfant, Newborn
dc.subjectFemale
dc.subjectMale
dc.subjectInfant, Extremely Premature
dc.titleSchool-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications